The headlines today said this was the first drug in 50 years approved to treat Lupus. It does not have a real good record of success but has given relief to 
many. This is good news and a far cry away from the last time we heard about the company with a doctor charged with inside trading relative to their stock.
Doctor Charged With Inside Trading Relating to Clinical Drug Trial Has Bail Set at 3 Million
Below is a copy of their current drug pipeline and it looks like an Anthrax inhalant recovery drug is also getting close. BD
The drug, made by Human Genome Sciences Inc., is designed to lessen the severity of lupus, a little-understood disease in which the body's immune system attacks tissues and organs, producing skin rashes, joint pain, chronic fatigue and in severe cases, heart and kidney complications.
Even though Benlysta has been shown to be only moderately successful in decreasing disease markers (an FDA advisory committee expressed some trepidation about its effectiveness last November), the dearth of other effective treatments makes Benlysta the hope of many a lupus researcher and patient.
Benlysta's noted side effects included infection, depression and suicide, all of which have delayed its approval.
0 comments :
Post a Comment